| Literature DB >> 18538000 |
Andreas Seidler1, Gaël Paul Hammer, Gabriele Husmann, Jochem König, Anne Krtschil, Irene Schmidtmann, Maria Blettner.
Abstract
AIM: To investigate the cancer risk among residents of Rhineland-Palatinate winegrowing communities in an ecological study.Entities:
Year: 2008 PMID: 18538000 PMCID: PMC2442109 DOI: 10.1186/1745-6673-3-12
Source DB: PubMed Journal: J Occup Med Toxicol ISSN: 1745-6673 Impact factor: 2.646
Characteristics of the Rhineland-Palatinate vineyard area
| Rhineland-Palatinate* | Area under wine (% of community area) | |||
| Total | > 0%, ≤ 5% | >5%, ≤ 20% | >20% | |
| Communities | 2,305 | 162 | 171 | 170 |
| Total area (ha) | 1,984,688 | 222,736 | 200,709 | 129,444 |
| Area under wine (ha) | 69,043 | 2,996 | 25,101 | 40,683 |
| % area under wine | 3.5% | 1.3% | 12.5% | 31.4% |
| Inhabitants (per ha) | 4,000,567 (2.02) | 564,210 (2.53) | 526,486 (2.62) | 301,193 (2.33) |
| Inhabitants per community (median, min-max) | 566 (6–184,752) | 1,188 (72–99,750) | 1,193 (95–80,535) | 984 (84–40,110) |
* All data pertain to Dec 31st, 1996 (Statistisches Landesamt Rheinland-Pfalz 2006)
Cancer risks (incidence rate ratios RR) in men with residence in communities with a large or medium area under wine cultivation vs. men in communities with low area under wine cultivation
| Reference* (1,665,594 PY†) | Area under wine cultivation > 5, ≤ 20% of community area (1,039,435 PY†) | Area under wine cultivation > 20% of community area (612,714 PY†) | |||||
| ICD-10 code | Cases | Cases | RR‡§ | 95% CI | Cases | RR‡§ | 95% CI |
| Head & neck (C00–C14) | 369 | 188 | 0.91 | 0.72–1.15 | 94 | 0.86 | 0.65–1.14 |
| Base of tongue (C01) | 35 | 11 | 0.53 | 0.26–1.08 | 10 | 0.87 | 0.40–1.91 |
| Other and unspecified parts of tongue (C02) | 35 | 26 | 1.22 | 0.72–2.07 | 13 | 1.12 | 0.56–2.25 |
| Floor of mouth (C04) | 42 | 25 | 0.98 | 0.57–1.70 | 11 | 0.70 | 0.34–1.47 |
| Palate (C05) | 22 | 15 | 1.24 | 0.62–2.49 | 5 | 0.88 | 0.31–2.54 |
| Other and unspecified parts of mouth (C06) | 18 | 8 | 0.71 | 0.29–1.73 | 3 | 0.45 | 0.12–1.71 |
| Parotid gland (C07) | 14 | 8 | 0.92 | 0.36–2.30 | 4 | 0.80 | 0.24–2.67 |
| Tonsil (C09) | 47 | 22 | 0.78 | 0.45–1.34 | 13 | 0.79 | 0.40–1.56 |
| Oropharynx (C10) | 35 | 15 | 0.78 | 0.39–1.57 | 5 | 0.48 | 0.17–1.34 |
| Piriform sinus (C12) | 20 | 10 | 0.90 | 0.41–2.02 | 8 | 1.67 | 0.66–4.25 |
| Hypopharynx (C13) | 56 | 27 | 0.76 | 0.46–1.26 | 17 | 0.88 | 0.48–1.62 |
| Oesophagus (C15) | 156 | 94 | 0.96 | 0.73–1.27 | 42 | 0.82 | 0.57–1.20 |
| Stomach (C16) | 241 | 166 | 1.06 | 0.86–1.31 | 92 | 1.03 | 0.79–1.34 |
| Small intestine (C17) | 24 | 14 | 0.92 | 0.45–1.86 | 2 | 0.21 | 0.05–0.95 |
| Colon, sigmoid & rectum (C18–C21) | 1188 | 806 | 1.07 | 0.95–1.21 | 460 | 1.10 | 0.96–1.26 |
| Colon (C18) | 723 | 473 | 1.04 | 0.91–1.20 | 268 | 1.06 | 0.90–1.25 |
| Rectosigmoid junction (C19) | 51 | 42 | 1.33 | 0.89–2.00 | 30 | 1.68 | 1.04–2.71 |
| Rectum (C20) | 397 | 284 | 1.13 | 0.94–1.35 | 157 | 1.10 | 0.89–1.37 |
| Anus and anal canal (C21) | 17 | 7 | 0.66 | 0.26–1.64 | 5 | 0.85 | 0.29–2.50 |
| Liver and intrahepatic bile ducts (C22) | 141 | 73 | 0.94 | 0.68–1.30 | 37 | 0.88 | 0.58–1.32 |
| Gallbladder & biliary tract (C23–C24) | 76 | 33 | 0.67 | 0.44–1.02 | 27 | 0.95 | 0.59–1.54 |
| Gallbladder (C23) | 17 | 7 | 0.58 | 0.23–1.46 | 7 | 0.96 | 0.36–2.53 |
| Other and unspecified parts of biliary tract (C24) | 59 | 26 | 0.70 | 0.43–1.13 | 20 | 0.95 | 0.55–1.65 |
| Pancreas (C25) | 162 | 99 | 1.03 | 0.78–1.36 | 51 | 0.96 | 0.68–1.37 |
| Nasal cavity and middle ear (C30–C31) | 18 | 9 | 0.73 | 0.32–1.67 | 4 | 0.51 | 0.16–1.62 |
| Larynx (C32) | 135 | 78 | 0.94 | 0.68–1.29 | 39 | 0.88 | 0.59–1.31 |
| Trachea, bronus and lung (C33–C34) | 1039 | 530 | 0.98 | 0.84–1.14 | 232 | 0.77 | 0.64–0.92 |
| Bronchus and lung (C34) | 1036 | 530 | 0.98 | 0.84–1.15 | 232 | 0.77 | 0.64–0.92 |
| Bone and articular cartilage (C40–C41) | 11 | 7 | 0.88 | 0.32–2.42 | 3 | 0.49 | 0.13–1.89 |
| Skin, malignant melanoma (C43) | 230 | 188 | 1.32 | 1.08–1.60 | 119 | 1.50 | 1.18–1.91 |
| Skin, other malignant neoplasms (C44) | 1990 | 1748 | 1.32 | 1.20–1.45 | 959 | 1.39 | 1.25–1.54 |
| Mesothelioma (C45) | 19 | 12 | 1.09 | 0.52–2.28 | 5 | 0.92 | 0.32–2.68 |
| Other connective and soft tissue (C49) | 32 | 35 | 1.65 | 1.00–2.70 | 9 | 0.68 | 0.31–1.48 |
| Breast (C50) | 14 | 9 | 1.02 | 0.43–2.39 | 3 | 0.60 | 0.16–2.25 |
| Penis (C60) | 20 | 15 | 1.17 | 0.56–2.44 | 6 | 0.71 | 0.26–1.93 |
| Prostate (C61) | 1857 | 1359 | 1.26 | 1.12–1.41 | 787 | 1.26 | 1.11–1.43 |
| Testis (C62) | 154 | 107 | 1.18 | 0.88–1.60 | 77 | 1.31 | 0.94–1.83 |
| Urinary tract (C64-C66+C68) | 330 | 206 | 1.03 | 0.85–1.26 | 107 | 0.96 | 0.75–1.23 |
| Kidney, except renal pelvis (C64) | 269 | 171 | 1.06 | 0.86–1.32 | 89 | 1.00 | 0.76–1.31 |
| Ureter (C66) | 30 | 7 | 0.35 | 0.15–0.80 | 7 | 0.58 | 0.24–1.39 |
| Bladder (C67, D09.0, D41.4) | 699 | 470 | 1.16 | 1.01–1.34 | 266 | 1.31 | 1.10–1.55 |
| Eye and adnexa (C69) | 15 | 8 | 1.02 | 0.43–2.43 | 3 | 0.88 | 0.23–3.37 |
| Meninges (C70) | 22 | 20 | 1.45 | 0.78–2.69 | 7 | 0.88 | 0.35–2.18 |
| Brain, CNS, meninges (C70–C72, D32–33, D42–43) | 133 | 90 | 1.08 | 0.81–1.44 | 53 | 1.04 | 0.73–1.49 |
| Brain (C71, D33, D43) | 109 | 70 | 1.02 | 0.74–1.41 | 45 | 1.06 | 0.72–1.57 |
| Thyroid gland (C73) | 33 | 23 | 1.11 | 0.64–1.92 | 16 | 1.31 | 0.68–2.53 |
| Hodgkin's disease (C81) | 40 | 24 | 0.86 | 0.51–1.46 | 12 | 0.64 | 0.32–1.27 |
| Follicular NHL (C82) | 29 | 21 | 1.23 | 0.67–2.25 | 19 | 1.98 | 1.01–3.85 |
| NHL (C82–C85) | 197 | 130 | 1.12 | 0.88–1.42 | 81 | 1.29 | 0.96–1.73 |
| Diffuse NHL (C83) | 122 | 66 | 0.91 | 0.66–1.24 | 31 | 0.80 | 0.52–1.23 |
| Peripheral and cutaneous T-cell lymphomas (C84) | 10 | 6 | 0.94 | 0.33–2.68 | 8 | 2.19 | 0.75–6.37 |
| Other and unspecified types of NHL (C85) | 36 | 37 | 1.64 | 1.03–2.59 | 23 | 1.84 | 1.05–3.23 |
| Multiple myeloma (C90) | 63 | 36 | 0.93 | 0.60–1.44 | 21 | 0.92 | 0.53–1.59 |
| Leukaemia (C91–C95) | 204 | 113 | 0.89 | 0.69–1.15 | 61 | 0.84 | 0.61–1.16 |
| Lymphoid leukaemia (C91) | 116 | 56 | 0.74 | 0.53–1.05 | 28 | 0.65 | 0.41–1.02 |
| Myeloid leukaemia (C92) | 77 | 52 | 1.09 | 0.75–1.59 | 27 | 0.99 | 0.61–1.60 |
| Primary site unspecified | 128 | 83 | 0.99 | 0.75–1.30 | 43 | 0.88 | 0.61–1.28 |
| All malignancies (excluding C44) | 7761 | 5024 | 1.12 | 1.05–1.19 | 2765 | 1.10 | 1.03–1.18 |
| All malignancies (including C44) | 9751 | 6772 | 1.15 | 1.09–1.22 | 3724 | 1.16 | 1.09–1.23 |
* Winegrowing communities with >0, <= 5% area under wine cultivation
† PY: Person-Years were approximated by population figures: the sum of population at the end of the year in the years under consideration.
‡ adjusted for age, rural or urban environment, and fruit cultivation
§ Poisson distribution of case counts assumed for: C45, C50, C70
Cancer risks (incidence rate ratios RR) in women with residence in communities with a large or medium area under wine cultivation vs. women in communities with low area under wine cultivation
| Reference* (1,778,184 PY†) | Area under wine cultivation > 5, ≤ 20% of community area (1,098,069 PY†) | Area under wine cultivation > 20% of community area (634,060 PY†) | |||||
| ICD-10 code | Cases | Cases | RR‡§ | 95% CI | Cases | RR‡§ | 95% CI |
| Head & neck (C00–C14) | 123 | 70 | 1.05 | 0.74–1.50 | 41 | 1.14 | 0.75–1.74 |
| Other and unspecified parts of tongue (C02) | 14 | 8 | 1.01 | 0.41–2.48 | 6 | 1.56 | 0.52–4.64 |
| Oropharynx (C10) | 19 | 6 | 0.53 | 0.20–1.39 | 5 | 0.81 | 0.28–2.39 |
| Oesophagus (C15) | 38 | 17 | 0.89 | 0.46–1.70 | 9 | 0.91 | 0.40–2.08 |
| Stomach (C16) | 197 | 147 | 1.27 | 1.01–1.60 | 61 | 1.07 | 0.79–1.47 |
| Small intestine (C17) | 24 | 17 | 1.17 | 0.64–2.15 | 8 | 1.04 | 0.45–2.40 |
| Colon, sigmoid & rectum (C18–C21) | 1122 | 733 | 1.04 | 0.92–1.17 | 346 | 0.94 | 0.81–1.09 |
| Colon (C18) | 734 | 509 | 1.11 | 0.97–1.28 | 214 | 0.90 | 0.75–1.08 |
| Rectosigmoid junction (C19) | 64 | 32 | 0.78 | 0.51–1.21 | 20 | 0.86 | 0.50–1.48 |
| Rectum (C20) | 301 | 180 | 0.95 | 0.78–1.17 | 108 | 1.06 | 0.83–1.35 |
| Anus and anal canal (C21) | 23 | 12 | 0.89 | 0.44–1.81 | 4 | 0.60 | 0.20–1.83 |
| Liver and intrahepatic bile ducts (C22) | 43 | 32 | 1.17 | 0.72–1.90 | 19 | 1.20 | 0.66–2.19 |
| Gallbladder & biliary tract (C23–C24) | 79 | 58 | 1.13 | 0.79–1.61 | 19 | 0.64 | 0.38–1.09 |
| Gallbladder (C23) | 39 | 38 | 1.44 | 0.89–2.33 | 10 | 0.64 | 0.30–1.34 |
| Other and unspecified parts of biliary tract (C24) | 40 | 20 | 0.78 | 0.46–1.34 | 9 | 0.63 | 0.29–1.34 |
| Pancreas (C25) | 158 | 85 | 0.97 | 0.72–1.29 | 40 | 0.93 | 0.64–1.37 |
| Larynx (C32) | 19 | 12 | 0.99 | 0.47–2.07 | 4 | 0.56 | 0.18–1.75 |
| Trachea, bronus and lung (C33–C34) | 342 | 168 | 0.99 | 0.77–1.27 | 94 | 1.19 | 0.88–1.59 |
| Bronchus and lung (C34) | 340 | 167 | 0.99 | 0.77–1.27 | 94 | 1.19 | 0.89–1.60 |
| Skin, malignant melanoma (C43) | 274 | 212 | 1.17 | 0.96–1.42 | 109 | 1.00 | 0.78–1.28 |
| Skin, other malignant neoplasms (C44) | 1710 | 1620 | 1.40 | 1.27–1.54 | 807 | 1.38 | 1.23–1.53 |
| Retroperitoneum and peritoneum (C48) | 10 | 9 | 1.72 | 0.65–4.53 | 4 | 1.93 | 0.53–7.02 |
| Other connective and soft tissue (C49) | 30 | 17 | 0.98 | 0.54–1.79 | 9 | 1.03 | 0.46–2.32 |
| Breast (C50) | 2525 | 1527 | 1.08 | 0.98–1.20 | 779 | 1.01 | 0.90–1.12 |
| Vulva (C51) | 63 | 36 | 0.98 | 0.64–1.50 | 22 | 1.23 | 0.72–2.10 |
| Vagina (C52) | 18 | 20 | 1.80 | 0.94–3.45 | 5 | 0.82 | 0.29–2.33 |
| Cervix uteri (C53) | 162 | 97 | 1.03 | 0.79–1.34 | 47 | 0.94 | 0.66–1.34 |
| Corpus uteri, (C54–C55) | 382 | 244 | 1.15 | 0.94–1.41 | 146 | 1.20 | 0.95–1.52 |
| Corpus uteri (C54) | 370 | 232 | 1.13 | 0.92–1.39 | 144 | 1.22 | 0.97–1.54 |
| Uterus, part unspecified (C55) | 12 | 12 | 1.58 | 0.70–3.59 | 2 | 0.46 | 0.10–2.17 |
| Ovary and other unspecified female genital organs (C56–C57) | 297 | 196 | 1.09 | 0.89–1.34 | 96 | 0.97 | 0.75–1.26 |
| Ovary (C56) | 284 | 183 | 1.07 | 0.86–1.32 | 93 | 0.99 | 0.76–1.28 |
| Other and unspecified female genital organs (C57) | 13 | 13 | 1.66 | 0.76–3.63 | 3 | 0.73 | 0.19–2.72 |
| Urinary tract (C64-C66+C68) | 208 | 136 | 1.10 | 0.86–1.40 | 73 | 1.04 | 0.77–1.40 |
| Kidney, except renal pelvis (C64) | 166 | 116 | 1.14 | 0.88–1.48 | 63 | 1.09 | 0.79–1.50 |
| Renal pelvis (C65) | 24 | 10 | 0.71 | 0.33–1.49 | 4 | 0.55 | 0.18–1.71 |
| Ureter (C66) | 16 | 10 | 1.02 | 0.45–2.29 | 4 | 0.75 | 0.23–2.44 |
| Bladder (C67, D09.0, D41.4) | 251 | 158 | 1.09 | 0.88–1.34 | 85 | 1.19 | 0.90–1.56 |
| Brain, CNS, meninges (C70–C72, D32–33, D42–43) | 167 | 105 | 1.11 | 0.84–1.46 | 62 | 1.25 | 0.89–1.75 |
| Meninges (C70) | 57 | 46 | 1.33 | 0.87–2.03 | 24 | 1.29 | 0.75–2.21 |
| Brain (C71, D33, D43) | 107 | 57 | 0.98 | 0.68–1.40 | 37 | 1.21 | 0.79–1.86 |
| Thyroid gland (C73) | 102 | 75 | 1.20 | 0.86–1.67 | 32 | 0.86 | 0.56–1.34 |
| Hodgkin's disease (C81) | 39 | 20 | 0.83 | 0.48–1.44 | 9 | 0.64 | 0.29–1.39 |
| NHL (C82–C85) | 220 | 114 | 0.93 | 0.72–1.21 | 52 | 0.78 | 0.56–1.09 |
| Follicular NHL (C82) | 50 | 18 | 0.58 | 0.34–1.01 | 5 | 0.29 | 0.11–0.76 |
| Diffuse NHL (C83) | 106 | 69 | 1.05 | 0.76–1.45 | 25 | 0.73 | 0.46–1.17 |
| Other and unspecified types of NHL (C85) | 56 | 24 | 0.71 | 0.43–1.14 | 19 | 1.07 | 0.61–1.89 |
| Multiple myeloma (C90) | 68 | 30 | 0.72 | 0.46–1.13 | 21 | 0.88 | 0.51–1.49 |
| Leukaemia (C91–C95) | 135 | 65 | 0.80 | 0.59–1.09 | 43 | 0.98 | 0.68–1.43 |
| Lymphoid leukaemia (C91) | 67 | 33 | 0.78 | 0.51–1.18 | 22 | 0.90 | 0.54–1.50 |
| Myeloid leukaemia (C92) | 60 | 32 | 0.90 | 0.59–1.37 | 16 | 0.92 | 0.51–1.66 |
| Primary site unspecified | 116 | 78 | 1.18 | 0.90–1.56 | 36 | 1.13 | 0.76–1.68 |
| All malignancies (excluding C44) | 7258 | 4508 | 1.09 | 1.03–1.17 | 2293 | 1.04 | 0.97–1.11 |
| All malignancies (including C44) | 8968 | 6128 | 1.14 | 1.08–1.21 | 3100 | 1.10 | 1.04–1.17 |
* Winegrowing communities with >0, <= 5% area under wine cultivation
† PY: Person-Years were approximated by population figures: the sum of population at the end of the year in the years under consideration.
‡ adjusted for age, rural or urban environment, and fruit cultivation
§ Poisson distribution of case counts assumed for: C21, C52, C55, C57, C65, C81
Cancer risks (standardized incidence ratios SIR) in men with residence in communities with planted winegrowing areas with the estimated incidence of cancer in the national population of Germany as reference
| Area under wine cultivation > 0, ≤ 5% of community area (1,665,594 PY†) | Area under wine cultivation > 5, ≤ 20% of community area (1,039,435 PY†) | Area under wine cultivation > 20% of community area (612,714 PY†) | ||||||||||
| ICD-10 code | Observed | Expected | SIR | 95% CI | Observed | Expected | SIR | 95% CI | Observed | Expected | SIR | 95% CI |
| Head & neck (C00–C14) | 369 | 238.00 | 1.13 | 1.01–1.25 | 188 | 205.94 | 0.91 | 0.79–1.05 | 94 | 117.54 | 0.80 | 0.65–0.98 |
| Stomach (C16) | 241 | 421.10 | 0.57 | 0.50–0.65 | 166 | 262.89 | 0.63 | 0.54–0.74 | 92 | 144.55 | 0.64 | 0.51–0.78 |
| Colon, sigmoid & rectum (C18–C21) | 1188 | 1445.33 | 0.82 | 0.78–0.87 | 806 | 906.16 | 0.89 | 0.83–0.95 | 460 | 497.93 | 0.92 | 0.84–1.01 |
| Trachea, bronchus and lung (C33–C34) | 1039 | 1376.19 | 0.75 | 0.71–0.80 | 530 | 865.12 | 0.61 | 0.56–0.67 | 232 | 478.60 | 0.48 | 0.42–0.55 |
| Skin, malignant melanoma (C43) | 230 | 257.40 | 0.89 | 0.78–1.02 | 188 | 160.19 | 1.17 | 1.01–1.35 | 119 | 91.08 | 1.31 | 1.08–1.56 |
| Prostate (C61) | 1857 | 1833.70 | 1.01 | 0.97–1.06 | 1359 | 1152.26 | 1.18 | 1.12–1.24 | 787 | 628.58 | 1.25 | 1.17–1.34 |
| Testis (C62) | 154 | 164.80 | 0.93 | 0.79–1.09 | 107 | 101.97 | 1.05 | 0.86–1.27 | 77 | 61.20 | 1.26 | 0.99–1.57 |
| Urinary tract (C64-C66+C68) | 330 | 392.87 | 0.84 | 0.75–0.94 | 206 | 247.03 | 0.83 | 0.72–0.96 | 107 | 137.47 | 0.78 | 0.64–0.94 |
| Bladder (C67, D09.0, D41.4) | 699 | 718.87 | 0.97 | 0.90–1.05 | 470 | 451.25 | 1.04 | 0.95–1.14 | 266 | 246.29 | 1.08 | 0.95–1.22 |
| NHL (C82–C85) | 197 | 255.32 | 0.77 | 0.67–0.89 | 130 | 160.18 | 0.81 | 0.68–0.96 | 81 | 90.11 | 0.90 | 0.71–1.12 |
| Leukaemia (C91–C95) | 204 | 253.60 | 0.80 | 0.70–0.92 | 113 | 158.75 | 0.71 | 0.59–0.86 | 61 | 89.49 | 0.68 | 0.52–0.88 |
| All malignancies (excluding C44) | 7761 | 8751.69 | 0.89 | 0.87–0.91 | 5024 | 5493.56 | 0.91 | 0.89–0.94 | 2765 | 3041.59 | 0.91 | 0.88–0.94 |
† PY: Person-Years were approximated by population figures: the sum of population at the end of the year in the years under consideration.
Cancer risks (standardized incidence ratios SIR) in women with residence in communities with planted winegrowing areas with the estimated incidence of cancer in the national population of Germany as reference
| Area under wine cultivation > 0, ≤ 5% of community area (1,665,594 PY†) | Area under wine cultivation > 5, ≤ 20% of community area (1,039,435 PY†) | Area under wine cultivation > 20% of community area (612,714 PY†) | ||||||||||
| ICD-10 code | Observed | Expected | SIR | 95% CI | Observed | Expected | SIR | 95% CI | Observed | Expected | SIR | 95% CI |
| Head & neck (C00–C14) | 123 | 93.17 | 1.32 | 1.10–1.58 | 70 | 57.01 | 1.23 | 0.96–1.55 | 41 | 31.13 | 1.32 | 0.95–1.79 |
| Stomach (C16) | 197 | 302.45 | 0.65 | 0.56–0.75 | 147 | 183.37 | 0.80 | 0.68–0.94 | 61 | 96.98 | 0.63 | 0.48–0.81 |
| Colon, sigmoid & rectum (C18–C21) | 1122 | 1529.06 | 0.73 | 0.69–0.78 | 733 | 929.83 | 0.79 | 0.73–0.85 | 346 | 491.03 | 0.70 | 0.63–0.78 |
| Trachea, bronchus and lung (C33–C34) | 342 | 429.49 | 0.80 | 0.71–0.89 | 168 | 263.51 | 0.64 | 0.54–0.74 | 94 | 142.96 | 0.66 | 0.53–0.80 |
| Skin, malignant melanoma (C43) | 274 | 314.29 | 0.87 | 0.77–0.98 | 212 | 191.68 | 1.11 | 0.96–1.27 | 109 | 107.56 | 1.01 | 0.83–1.22 |
| Breast (C50) | 2525 | 2332.19 | 1.08 | 1.04–1.13 | 1527 | 1429.33 | 1.07 | 1.02–1.12 | 779 | 786.82 | 0.99 | 0.92–1.06 |
| Cervix uteri (C53) | 162 | 239.01 | 0.68 | 0.58–0.79 | 97 | 145.48 | 0.67 | 0.54–0.81 | 47 | 83.17 | 0.57 | 0.42–0.75 |
| Corpus uteri, (C54–C55) | 382 | 309.64 | 1.23 | 1.11–1.36 | 244 | 190.05 | 1.28 | 1.13–1.46 | 146 | 102.37 | 1.43 | 1.20–1.68 |
| Ovary and other unspecified female genital organs (C56–C57) | 297 | 449.08 | 0.66 | 0.59–0.74 | 196 | 273.91 | 0.72 | 0.62–0.82 | 96 | 149.12 | 0.64 | 0.52–0.79 |
| Urinary tract (C64-C66+C68) | 208 | 261.56 | 0.80 | 0.69–0.91 | 136 | 160.51 | 0.85 | 0.71–1.00 | 73 | 86.15 | 0.85 | 0.66–1.07 |
| Bladder (C67, D09.0, D41.4) | 251 | 325.54 | 0.77 | 0.68–0.87 | 158 | 200.30 | 0.79 | 0.67–0.92 | 85 | 107.82 | 0.79 | 0.63–0.97 |
| NHL (C82–C85) | 220 | 286.04 | 0.77 | 0.67–0.88 | 114 | 175.38 | 0.65 | 0.54–0.78 | 52 | 95.33 | 0.55 | 0.41–0.72 |
| Leukaemia (C91–C95) | 135 | 228.14 | 0.59 | 0.50–0.70 | 65 | 139.57 | 0.47 | 0.36–0.59 | 43 | 75.32 | 0.57 | 0.41–0.77 |
| All malignancies (excluding C44) | 7258 | 8285.78 | 0.88 | 0.86–0.90 | 4508 | 5070.41 | 0.89 | 0.86–0.92 | 2293 | 2740.00 | 0.84 | 0.80–0.87 |
† PY: Person-Years were approximated by population figures: the sum of population at the end of the year in the years under consideration.